Institute of Genetics and Animal Breeding of the Polish Academy of Sciences

ighz.edu.pl

The Institute has a prestigious status of the Leading National Research Centre granted by the Polish Ministry of Science and Higher Education. The principal fields of the Institute’s activity include basic research on molecular genetics, cytogenetics, experimental embryology and biotechnology, as well as the genetic background to the physiology of stress and animal etiology. Research in applied sciences is conducted in the fields of population genetics, animal breeding, as also animal maintenance and production systems. Studies on animal behaviour and welfare are an important complement. The principal aim of research in applied sciences is the elaboration of such methods of animal improvement and production, which render possible the production of safe and valuable food, simultaneously retaining a high level of animal welfare and a limited unfavourable effect of agriculture on the environment.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

INDUSTRIAL IMPACT

ARCTIC VISION ANNOUNCES FIRST PATIENT ENROLLED IN PHASE III CLINICAL TRIAL OF ARVN003 FOR PRESBYOPIA

Arctic Vision | July 05, 2022

news image

Arctic Vision, a China-based biotech company focused on innovative ophthalmic therapies, announced that the first patient has been enrolled in a Phase III clinical study evaluating ARVN003, a proprietary pilocarpine formulation leveraging its micro dosing platform Optejet®, as a treatment to temporarily improve vision in adults with presbyopia in China. The Phase III study is double-masked, placebo-controlled, randomized, and multicenter trial evaluating the efficacy and safet...

Read More

INDUSTRIAL IMPACT

TRANSPERFECT LIFE SCIENCES AND INNOVADERM RESEARCH EXPAND TRIAL INTERACTIVE PARTNERSHIP

TransPerfect Life Sciences | February 16, 2022

news image

TransPerfect Life Sciences, a leading provider of services and technologies to support global clinical trials and product development for the biopharmaceutical industry, today announced that Innovaderm will scale their implementation of Trial Interactive to further enable and optimize remote clinical operations. Innovaderm, a North America-based contract research organization (CRO) that specializes in clinical studies for dermatology, leveraged Trial Interactive remote monitoring ...

Read More

CELL AND GENE THERAPY, INDUSTRIAL IMPACT

AZENTA ANNOUNCES LAUNCH OF CRYO STORE PICO

Azenta Life Sciences | February 28, 2023

news image

On February 27, 2023, Azenta Life Sciences, a leading provider of life sciences solutions, announced the launch of its latest automated cryogenic storage system, the Cryo Store PicoTM. This new product is designed to store high-value biological samples used throughout various stages of the life sciences industry, from research and development to clinical use. Azenta is already known for providing innovative automated cryogenic solutions such as the BioStore™ III...

Read More

ARBOR VITA LAUNCHES OPEN PLATFORM COVID-19 ANTIBODY TEST EXPANDING ACCESS TO HIGHER QUALITY DIAGNOSTICS

Arbor Vita | June 08, 2020

news image

Arbor Vita announced today the availability of its CoVisa™ IgG ELISA-based test for antibodies associated with the novel coronavirus (COVID-19). The test has been found to have a 100 percent sensitivity (positive percentage agreement), and 99.24 percent specificity (negative percentage). Additional validation testing is ongoing in independent laboratories. The company has notified the U.S. Food and Drug Administration under the Emergency Use Authorization (EUA) process.Arbor Vita'...

Read More
news image

INDUSTRIAL IMPACT

ARCTIC VISION ANNOUNCES FIRST PATIENT ENROLLED IN PHASE III CLINICAL TRIAL OF ARVN003 FOR PRESBYOPIA

Arctic Vision | July 05, 2022

Arctic Vision, a China-based biotech company focused on innovative ophthalmic therapies, announced that the first patient has been enrolled in a Phase III clinical study evaluating ARVN003, a proprietary pilocarpine formulation leveraging its micro dosing platform Optejet®, as a treatment to temporarily improve vision in adults with presbyopia in China. The Phase III study is double-masked, placebo-controlled, randomized, and multicenter trial evaluating the efficacy and safet...

Read More
news image

INDUSTRIAL IMPACT

TRANSPERFECT LIFE SCIENCES AND INNOVADERM RESEARCH EXPAND TRIAL INTERACTIVE PARTNERSHIP

TransPerfect Life Sciences | February 16, 2022

TransPerfect Life Sciences, a leading provider of services and technologies to support global clinical trials and product development for the biopharmaceutical industry, today announced that Innovaderm will scale their implementation of Trial Interactive to further enable and optimize remote clinical operations. Innovaderm, a North America-based contract research organization (CRO) that specializes in clinical studies for dermatology, leveraged Trial Interactive remote monitoring ...

Read More
news image

CELL AND GENE THERAPY, INDUSTRIAL IMPACT

AZENTA ANNOUNCES LAUNCH OF CRYO STORE PICO

Azenta Life Sciences | February 28, 2023

On February 27, 2023, Azenta Life Sciences, a leading provider of life sciences solutions, announced the launch of its latest automated cryogenic storage system, the Cryo Store PicoTM. This new product is designed to store high-value biological samples used throughout various stages of the life sciences industry, from research and development to clinical use. Azenta is already known for providing innovative automated cryogenic solutions such as the BioStore™ III...

Read More
news image

ARBOR VITA LAUNCHES OPEN PLATFORM COVID-19 ANTIBODY TEST EXPANDING ACCESS TO HIGHER QUALITY DIAGNOSTICS

Arbor Vita | June 08, 2020

Arbor Vita announced today the availability of its CoVisa™ IgG ELISA-based test for antibodies associated with the novel coronavirus (COVID-19). The test has been found to have a 100 percent sensitivity (positive percentage agreement), and 99.24 percent specificity (negative percentage). Additional validation testing is ongoing in independent laboratories. The company has notified the U.S. Food and Drug Administration under the Emergency Use Authorization (EUA) process.Arbor Vita'...

Read More